Takeda Pharmaceutical Limited

TAK | NYSE

Price Alert Chart Builder DCF Calculator

$18.89

-$0.02 (-0.11%)

At close: Sep 21, 2026, 4:00 PM ET

$19.18

+$0.29 (+1.56%)

Pre-market: Sep 22, 2026, 9:11 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Dividends Profile

Income Statement Balance Sheet Cashflow Statement Ratios

Annual Quarterly TTM

Fiscal Year Period Ending	FY 2025 Mar 30, 2026	FY 2024 Mar 30, 2025	FY 2023 Mar 30, 2024	FY 2022 Mar 30, 2023	FY 2021 Mar 30, 2022	FY 2020 Mar 30, 2021
Revenue	4.78T	4.58T	4.26T	4.03T	3.57T	3.2T
Cost of Revenue	2.34T	1.58T	1.43T	1.24T	1.11T	994.31B
Gross Profit	2.44T	3T	2.83T	2.78T	2.46T	2.2T
Operating Income	573.04B	342.59B	214.08B	490.51B	460.84B	509.27B
Interest Income	223.91B	19.64B	78.1M	5.51B	4.59B	1.78B
Pretax Income	275.88B	175.08B	52.79B	375.09B	302.57B	366.24B
Net Income	203.33B	107.93B	144.07B	317.02B	230.06B	376.01B
Selling & General & Admin	1.15T	1.1T	1.05T	997.31B	886.36B	875.66B
Research & Development	716.69B	730.23B	729.92B	633.33B	526.09B	455.83B
Other Expenses	n/a	823.76B	834.44B	662.27B	588.87B	362.74B
Operating Expenses	1.87T	2.66T	2.62T	2.29T	2T	1.69T
Interest Expense	379.14B	137.31B	1.06B	116.97B	122.43B	130.81B
Selling & Marketing Expenses	n/a	n/a	n/a	n/a	n/a	n/a
Cost & Expenses	4.2T	4.24T	4.05T	3.54T	3.11T	2.69T
Income Tax Expense	72.27B	66.94B	-91.41B	58.05B	72.41B	-9.94B
Shares Outstanding (Basic)	3.15B	3.21B	3.13B	3.1B	3.13B	3.12B
Shares Outstanding (Diluted)	3.21B	3.21B	3.16B	3.14B	3.15B	3.15B
EPS (Basic)	63.91	34.17	46.05	102.15	73.57	120.36
EPS (Diluted)	63.91	33.62	45.58	100.97	72.94	119.48
EBITDA	1.42T	1.21T	1.14T	1.28T	1.18T	983.72B
EBIT	655.02B	449.12B	499.48B	619.67B	600.06B	424.05B
Depreciation & Amortization	764.62B	761.4B	644.46B	664.4B	583.15B	559.67B